ASSERTIO THERAPEUTICS, INC. ASRT Income Statement

Assertio therapeutics, inc. (ASRT)

Income statement / Yearly

Dec'19	Dec'18	Dec'17	Dec'16	Dec'15	Dec'14	Dec'13	Dec'12	Dec'11	Dec'10	Dec'09
Revenues:
Total revenues
229,504	311,770	380,724	455,897	342,735	390,363	134,205	90,816	132,973	80,764	57,728
License and other revenue
-	-	-	-	-	31,515	12,796	18,798	81,798	34,821	21,101
Non-cash PDL royalty revenue
-	-	-	-	-	242,808	18,104	-	-	-	-
Costs and expenses:
Cost of sales (excluding amortization of intangible assets)
9,505	18,476	72,598	87,414	67,898	15,146	7,091	6,039	5,544	8,097	5,257
Research and development expenses
10,106	8,042	13,718	-	-	-	-	-	-	-	-
Research and development expenses
-	-	-	32,631	17,541	7,116	8,073	15,462	15,187	20,111	34,298
Acquired in-process research and development
0	0	24,900	0	54,900	-	-	-	-	-	-
Promotion fee expense
-	-	-	-	-	-	-	-	27,339	31,419	23,589
Other selling, general and administrative expense
-	-	-	-	-	-	-	-	54,205	17,512	16,656
Selling, general and administrative expenses
108,866	119,218	195,696	204,498	199,352	121,126	105,176	97,646	81,544	48,931	40,245
Amortization of intangible assets
101,774	101,774	102,745	106,845	83,344	10,161	4,548	2,022	-	-	-
Loss on impairment of intangible asset
189,790	0	0	-	-	-	-	-	-	-	-
Loss on impairment of intangible asset
189,790	0	0	-	-	-	-	-	-	-	-
Restructuring Charges
3,891	20,601	13,247	0	-	-	-	-	-	-	-
Gain on settlement agreement
-	-	-	-	-	-	-	-	40,000	-	0
Total costs and expenses
423,932	268,111	422,904	431,388	393,135	153,549	124,888	121,169	62,275	77,139	79,800
(Loss) income from operations
-194,428	43,659	-42,180	24,509	-50,400	236,814	9,317	-30,353	70,698	3,625	-22,072
Other income (expense):
Interest and other income
-	-	-	485	599	215	662	520	557	839	1,050
Gain (Loss) on Extinguishment of Debt
-	-	-	-5,777	-	-	-	-	-	-	-
Interest expense
58,389	68,881	73,552	83,719	73,436	9,275	911	39	133	572	1,001
Litigation settlement
0	62,000	0	0	29,900	-	-	-	-	-	-
Gain on debt extinguishment
26,385	0	0	-	-	-	-	-	-	-	-
Other
3,948	1,197	681	-	-	-	-	-	-	-	-
Gain (Loss) on Disposition of Intangible Assets
0	0	17,064	0	-	-	-	-	-	-	-
Non-cash interest expense on PDL liability
-	-	-	-	-	14,646	4,488	-	-	-	-
Total other income (expense)
-28,056	-5,684	-61,745	-	-72,837	-23,706	-4,737	481	424	267	49
Net income (loss) before income taxes
-222,484	37,975	-103,925	-64,502	-123,237	213,108	4,580	-29,872	71,122	3,892	-22,023
Income tax expense
-5,283	1,100	-1,429	24,200	-47,499	81,346	-38,733	-91	396	-4	-15
Net Income (Loss) Attributable to Parent
-217,201	36,908	-102,496	-88,720	-75,738	131,762	43,313	-29,781	70,726	3,896	-22,008
Unrealized gain on available-for-sale securities, net of tax
0	0	14	-	-	-	-	-	-	-	-
Other comprehensive income:
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent
5	-	14	-	-	-	-	-	-	36	-
Comprehensive income (loss)
-217,201	36,908	-102,482	-	-	-	-	-	-	3,932	-
Basic net income (loss) per share (in dollars per share)
-3.07	0.58	-1.63	-1.45	-	2.26	0.76	-0.53	1.30	0.07	-0.43
Diluted net income (loss) per share (in dollars per share)
-3.07	0.57	-1.63	-1.45	-	2.05	0.75	-0.53	1.26	0.07	-0.43
Shares used in computing basic net income (loss) per share (in shares)
70,716	63,794	62,702	61,297	-	58,292	56,736	55,892	54,562	52,533	51,519
Shares used in computing diluted net income (loss) per share (in shares)
70,716	64,208	62,702	61,297	-	66,307	57,543	55,892	56,089	53,463	51,519
Basic and diluted net loss per share (in dollars per share)
-	-	-	-	-1.26	-	-	-	-	-	-
Shares used in computing basic and diluted net loss per share (in shares)
-	-	-	-	60,116	-	-	-	-	-	-
Product sales, net
Total revenues
108,806	129,966	379,880	455,066	341,750	114,219	58,302	27,483	41,178	45,637	35,094
Commercialization agreement, net
Total revenues
118,614	155,743	0	0	-	-	-	-	-	-	-
Royalties and milestones
Total revenues
2,084	26,061	844	831	985	1,821	45,003	44,535	9,997	306	1,533
Senior Notes
Loss on prepayment of Senior Notes
0	0	5,938	-	-	-	-	-	-	-	-